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EDITORIAL COMMENT
Acute Myocardial
Infarction: Are
Diabetics Different?*
Spencer B. King III, MD, MACC
Atlanta, Georgia
Before considering whether diabetic patients undergoing
myocardial infarction (MI) should be treated differently, let
us consider diabetic patients with coronary artery disease
and those who undergo interventional procedures. There is
ample evidence from Framingham and elsewhere that dia-
betes carries a high risk for cardiac mortality (1). This is due
to the premature development of atherosclerosis often
associated with more diffuse coronary disease (2) and worse
left ventricular function (3). The progression of coronary
artery disease in diabetics has long been recognized and may
be related to increased insulin-like growth factor, platelet-
derived growth factor, insulin, and other substances that
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may promote atherogenesis (4), endothelial dysfunction,
enhanced platelet aggregation and thrombus formation (5).
The relationship of serum glucose level is unclear; however,
hemoglobin A1C levels do seem to predict cardiovascular
events (6). Recently the role of oxidative stress on platelet
function has been explored (7).
Coronary angioplasty in diabetics has been a subject of
interest since the technique was developed. The success rate
of angioplasty increased and the complication rates fell in
the two National Heart, Lung and Blood Institute registries
comparing results from the late 1970s to the mid 1980s.
This occurred despite an increasing number of diabetic
patients in the latter cohort (8). Improved equipment and
operator experience undoubtedly accounted for the im-
provement in this series as well as others (9,10).
The outcome of 1,133 diabetic patients treated at Emory
University Hospital (Atlanta, Georgia) over a 10-year pe-
riod was reviewed (11). The procedural success rates were
similar between diabetic and nondiabetic patients, although
a trend for an increased death and MI rate was present in
insulin-requiring diabetics. The registry of the Society for
Cardiac Angiography and Interventions (12) analyzing
10,622 patients found that diabetes had no independent
association with adverse outcome. A similar finding was
present in a study by the Multi-Hospital Eastern Atlantic
Restenosis Trial investigators (13). Most of the patients in
these series had single-vessel disease. Ellis et al. (9) found
that among patients with multivessel disease, lesion classi-
fication and diabetes were the only independent variables of
procedure outcome, with ischemic complications occurring
in 15.4% of the diabetic patients and 5.8% of the nondia-
betic patients. However, in an analysis of 8,207 patients
treated at Emory University Hospital and the San Francisco
Heart Institute in the mid 1980s, diabetes did not predict
the occurrence of acute closure (10). It should be pointed
out, however, that once acute closure occurred, diabetes was
a significant predictor of mortality (38.5% in diabetics
compared with 11% in nondiabetics, p 5 0.024).
Restenosis and long-term outcome is also impacted by
the presence of diabetes. Conventional angioplasty has
consistently shown a statistically higher restenosis rate
among patients with diabetes (14,15). Long-term survival of
patients undergoing multivessel coronary angioplasty has
been brought into question by the findings of a large series
from Emory (16) as well as long-term findings of the Bypass
Angioplasty Revascularization Investigation (BARI) and
Emory Angioplasty versus Surgery Trial (EAST) trials
(17,18). The recent advances in interventional cardiology,
including stenting and potent antiplatelet therapy, may alter
these findings (19,20).
The article by Hasdai et al. (21) takes as its initial premise
that the outcome of acute MI therapy with thrombolytics is
associated with a significantly worse outcome in diabetics
than in nondiabetics, as shown in the Global Use of
Strategies to Open Occluded Arteries in Acute Coronary
Syndromes (GUSTO-1) trial. The current article in this
issue of the Journal (21), examines the angiographic sub-
study of patients undergoing thrombolysis or primary an-
gioplasty in the GUSTO-IIb study. This study compared
the acute and early outcomes of 177 diabetics with the
outcomes of 961 nondiabetics who were randomized be-
tween thrombolysis and primary angioplasty. The study was
convincing in showing a reduction in death, reinfarction or
disabling stroke in the nondiabetic group. The authors
contend that a similar trend was present for the diabetics;
however, this did not reach statistical significance. It is
mildly reassuring that among diabetics, this composite end
point was somewhat lower at 30 days in the angioplasty
group (11 of 99) as compared with the thrombolysis group
(13 of 78). Of concern, however, is the fact that the
in-hospital mortality, although not showing a significant
difference, was 5.1% in the thrombolysis group, which
paralleled the nondiabetic results, but was 9.1% in the
angioplasty group. The authors also note that mortality
remained higher for the angioplasty group at six months,
although there was no significant difference at one year. The
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angiographic study documented that Thrombolysis in Myo-
cardial Infarction (TIMI) 3 flow among patients undergo-
ing angioplasty was achieved in a similar percentage of
diabetic and nondiabetic patients (73.1% vs. 78.1%). Al-
though these figures indicate that the diabetic patients had
comparable success with primary angioplasty, the results in
both groups are disappointing. It would be hoped that
TIMI 3 flow rates could be achieved perhaps approaching
those seen in other primary angioplasty versus thrombolysis
trials (22,23). It should be pointed out, however, that
different core laboratory assessments of TIMI 3 flow may
artificially exaggerate the differences.
One might speculate as to the reason why well accepted
differences in long-term outcome in diabetic patients might
not be reflected in the acute outcome of primary infarct
angioplasty. The long-term outcome of patients depends in
great measure on the magnitude of the disease state and the
systemic factors that predispose the patient to progression of
disease as well as restenosis. These factors clearly impact
long-term survival of diabetic patients; current investiga-
tions into effective secondary preventive measures, including
the value of tight glycemic control, are the subject of a great
deal of ongoing research. The outcome of acute infarct
angioplasty, however, depends in great measure on the
ability to interrupt the infarction. In the time frame covered
by the present study, one would not expect disease progres-
sion or restenosis to play a role, but factors such as more
extensive disease in the diabetic patients could have influ-
enced the postprocedure mortality. The use of the compos-
ite end point, although very popular in current clinical trials,
does not give a complete picture. Whereas reinfarction in
the diabetic group was significantly greater in the throm-
bolysis cohort, mortality trended in the opposite direction.
These events should not be equated and one may also
speculate that they are influenced by different aspects of the
diabetic condition. Reinfarction may be driven by the
prothrombotic features present in diabetic patients, while
the early mortality may be linked to more extensive disease
commonly present.
How can the outcomes of therapy for acute infarction be
further improved? In the GUSTO IIb study, stenting and
GPIIb/IIIa receptor blocking agents were rarely utilized.
The impact of IIb/IIIa agents in diabetic patients has been
dramatic in reducing periprocedural MI (19), although no
documentation of early mortality improvement has been
claimed. Likewise, coronary stenting (23) has been effective
in reducing recurrent ischemia and reintervention although
not improving periprocedural mortality.
One must agree with the conclusion that primary angio-
plasty should not be denied in diabetic patients. After all,
primary angioplasty is basically an emergency procedure
designed to save lives, while preventing recurrent ischemia
and late restenosis are secondary objectives. Additional
measures currently available and yet to be developed are
needed to improve both short- and long-term survival in
diabetic patients.
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